share_log

Cardio Diagnostics Holdings | S-3: Registration statement for specified transactions by certain issuers

Cardio Diagnostics Holdings | S-3:特定交易注册声明

美股sec公告 ·  01/26 17:20
Moomoo AI 已提取核心信息
Cardio Diagnostics Holdings, Inc. (Cardio) has filed a Form S-3 with the Securities and Exchange Commission (SEC) on January 26, 2024, for a proposed public offering of securities. The registration statement includes common stock, preferred stock, warrants, units, and subscription rights, with the potential to raise up to $17.0 million. Cardio, a company focused on developing products for cardiovascular diseases leveraging AI-driven genetic-epigenetic technology, has not declared dividends historically and has incurred net losses in recent years. The company plans to use the net proceeds for general corporate purposes, including working capital. Cardio's common stock and public warrants are listed on the Nasdaq Capital Market under the symbols 'CDIO' and 'CDIOW' respectively. The offering will be made through an 'at...Show More
Cardio Diagnostics Holdings, Inc. (Cardio) has filed a Form S-3 with the Securities and Exchange Commission (SEC) on January 26, 2024, for a proposed public offering of securities. The registration statement includes common stock, preferred stock, warrants, units, and subscription rights, with the potential to raise up to $17.0 million. Cardio, a company focused on developing products for cardiovascular diseases leveraging AI-driven genetic-epigenetic technology, has not declared dividends historically and has incurred net losses in recent years. The company plans to use the net proceeds for general corporate purposes, including working capital. Cardio's common stock and public warrants are listed on the Nasdaq Capital Market under the symbols 'CDIO' and 'CDIOW' respectively. The offering will be made through an 'at the market offering' agreement with Craig-Hallum Capital Group LLC, allowing sales directly into the market at varying prices. The company's management will have broad discretion over the use of the net proceeds, and there is no guarantee of the minimum amount raised. The offering may result in dilution for current shareholders and the stock may become the target of a 'short squeeze' due to market volatility.
Cardio Diagnostics Holdings, Inc.(Cardio)已于2024年1月26日向美国证券交易委员会(SEC)提交了S-3表格,要求进行证券公开发行。注册声明包括普通股、优先股、认股权证、单位和认购权,可能筹集高达1700万美元的资金。Cardio是一家专注于利用人工智能驱动的遗传表观遗传学技术开发心血管疾病产品的公司,该公司历来没有宣布分红,近年来也出现了净亏损。该公司计划将净收益用于一般公司用途,包括营运资金。Cardio的普通股和公开认股权证分别在纳斯达克资本市场上市,代码分别为 “CDIO” 和 “CDIOW”。此次发行将通过与Craig-Hallum Capital Group LLC签订的 “市场发行” 协议进行,允许以不同的价格直接向市场销售。公司的管理层将对净收益的使用拥有广泛的自由裁量权,并且无法保证最低筹集金额。此次发行可能会导致现有股东稀释,由于市场波动,该股可能成为 “空头挤压” 的目标。
Cardio Diagnostics Holdings, Inc.(Cardio)已于2024年1月26日向美国证券交易委员会(SEC)提交了S-3表格,要求进行证券公开发行。注册声明包括普通股、优先股、认股权证、单位和认购权,可能筹集高达1700万美元的资金。Cardio是一家专注于利用人工智能驱动的遗传表观遗传学技术开发心血管疾病产品的公司,该公司历来没有宣布分红,近年来也出现了净亏损。该公司计划将净收益用于一般公司用途,包括营运资金。Cardio的普通股和公开认股权证分别在纳斯达克资本市场上市,代码分别为 “CDIO” 和 “CDIOW”。此次发行将通过与Craig-Hallum Capital Group LLC签订的 “市场发行” 协议进行,允许以不同的价格直接向市场销售。公司的管理层将对净收益的使用拥有广泛的自由裁量权,并且无法保证最低筹集金额。此次发行可能会导致现有股东稀释,由于市场波动,该股可能成为 “空头挤压” 的目标。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息